ENTRY       D12356                      Drug
NAME        Zilucoplan sodium (JAN);
            Zilbrysq (TN)
FORMULA     C172H274N24O55. 4Na
EXACT_MASS  3647.8972
MOL_WEIGHT  3650.1028
REMARK      Therapeutic category: 3999
            Chemical structure group: DG03224
            Product (DG03224): D12356<JP>
EFFICACY    Autoimmune disease treatment, Complement C5 inhibitor
  DISEASE   Generalized myasthenia gravis (antiacetylcholine receptor antibody positive) [DS:H01594]
TARGET      C5 [HSA:727] [KO:K03994]
  PATHWAY   hsa04080(727)  Neuroactive ligand-receptor interaction
            hsa04610(727)  Complement and coagulation cascades
            hsa04613(727)  Neutrophil extracellular trap formation
BRITE       Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D12356  Zilucoplan sodium (JAN)
            Target-based classification of drugs [BR:br08310]
             Not elsewhere classified
              Organismal systems
               Complement and coagulation
                C5
                 D12356  Zilucoplan sodium (JAN) &lt;JP&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D12356
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D12356
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D12356
///
